News >

Bristol-Myers Squibb Acquires Celgene Corporation

Kristi Rosa
Published: Thursday, Jan 03, 2019

Dr. Giovanni Caforio

Giovanni Caforio, MD
Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement with Celgene Corporation under which BMS will acquire Celgene in a cash and stock transaction with an equity value of about billion.1

Among the 6 products, 4 are in hematology, which include luspatercept, lisocabtagene maraleucel (liso-cel; JCAR017), bb2121, and fedratinib. Two products are in immunology and inflammation, which are TYK2 and ozanimod.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication
x